# Verantos

> Verantos is a Menlo Park healthcare technology company that turns messy, fragmented patient records - including the clinical notes most platforms ignore - into research-grade real-world evidence (RWE) at scale. Using AI applied to the complete patient record and a rigorous focus on measured accuracy, completeness, and traceability, Verantos helps pharmaceutical companies, regulators, and health systems generate evidence that can hold up to FDA-grade scrutiny across every therapeutic area.

- **Founded:** 2015
- **Headquarters:** Menlo Park, California, United States
- **Founders:** Dan Riskin (Founder & CEO)
- **Team size:** ~85 employees
- **Products:** Verantos Evidence Platform, Pragmatic Registry, Research Network
- **Notable:** First company to generate research-grade real-world evidence at scale across all therapeutic areas, Selected for FDA grant program supporting use of real-world data in regulatory decision-making, Awarded SBIR Phase II grant (~$1.5M) from NCATS at the NIH (2018)

## Products & services

- **Verantos Evidence Platform** — A curation, linkage, and enrichment platform (launched September 2022) that applies AI to the complete patient record - structured data plus unstructured clinical narratives - to generate real-world evidence with measured accuracy, completeness, and traceability that meets the highest evidentiary standards, including FDA draft guidance.
- **Pragmatic Registry** — Disease-specific registries built from routinely collected real-world data, curated for clinical accuracy and completeness and delivered in standardized OMOP CDM format for use in clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives.
- **Research Network** — A growing federated network of de-identified, linkable real-world data from health systems and data partners, enabling representative, high-validity patient cohorts at scale.

## Achievements

- First company to generate research-grade real-world evidence at scale across all therapeutic areas
- Selected for FDA grant program supporting use of real-world data in regulatory decision-making
- Awarded SBIR Phase II grant (~$1.5M) from NCATS at the NIH (2018)
- Deloitte Technology Fast 500 - ranked #189 in North America (2023)
- Inc. 5000 fastest-growing companies - ranked #224 (2022)
- Launched the Verantos Evidence Platform for high-validity RWE (September 2022)

## Latest updates

- **2026-03** — CEO Dan Riskin featured on The Healthcare Technology Report podcast, detailing how Verantos measures data quality via accuracy, completeness, and traceability and built a severe asthma dataset for a top pharma partner.
- **2025-08** — Verantos presented practical approaches in high-validity real-world evidence generation at the ISPE 41st Annual Meeting.
- **2024-04** — Announced partnership with CuriMeta, adding ~7 million de-identified patients to its Research Network.
- **2023-11** — Named to the Deloitte Technology Fast 500 (#189 in North America).
- **2022-09** — Launched the Verantos Evidence Platform for high-validity real-world evidence.

## Links

- Website: https://verantos.com
- LinkedIn: https://www.linkedin.com/company/verantos
- Twitter/X: https://twitter.com/verantosrwe
- YouTube: https://www.youtube.com/watch?v=LfVLRQbwHZE

---

Profile page: https://yespress.io/verantos
Published by YesPress — https://yespress.io
Last updated: 2026-06-20